CANNABINOIDS, ENDOCANNABINOID SYSTEM AND COGNITIVE FUNCTIONS: FOES OR FRIENDS?

被引:0
|
作者
Kitchigina, V. F. [1 ]
机构
[1] RAS, Inst Theoret & Expt Biophys, Pushchino, Russia
关键词
endocannabinoids; retrograde transmission; cognitive functions; learning; memory; consolidation; neurotransmitters; Alzheimer's disease; temporal lobe epilepsy; protection; ACID AMIDE HYDROLASE; EXECUTIVE FUNCTION DEFICITS; FACIAL EMOTION RECOGNITION; MEDIAL PREFRONTAL CORTEX; SPATIAL WORKING-MEMORY; RECEPTOR-KNOCKOUT MICE; SHORT-TERM-MEMORY; CB1; RECEPTOR; ALZHEIMERS-DISEASE; BASOLATERAL AMYGDALA;
D O I
10.31857/S0044467721010068
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cannabinoids are natural compounds found in hemp (Cannabis sativa). Scientific interest in cannabinoids arose after the discovery of the main psychoactive component in cannabis, Delta 9-tetrahy-drocannabinol. Subsequently, receptors on which it acts were identified in the brain, as well as ligands of these receptors, endogenous cannabinoids (ECs), which together with the enzymes of their synthesis, transport and degradation form the endacannabinoid system (ECS). Interest in ECs has steadily increased in recent years, especially after the discovery of their important role in cognitive functions. They are regulators of synaptic transmission in the brain, mediate numerous forms of plasticity and control neural energy metabolism. They exert their influence through a number of mechanisms and interactions with neurotransmitters, neurotrophic factors and neuropeptides. The main function of ECs in the brain is to perform retrograde synaptic signaling and neuromodulation, owing to which cell homeostasis is maintained. Information on the effect of cannabinoid drugs on cognitive functions is very contradictory. The reasons for the contradictions may lie in the fact that strict scientific data from clinical and socio-logical studies are not yet sufficient, and in experiments on animals, different authors use different methods and approaches for influencing the EC system. Thus, the effects may vary depending on the drugs used, their dose and method of administration, as well as on the tasks and experimental conditions selected for testing. There is extensive literature indicating the protective effect of the ECS activation in neurodegenerative diseases in humans and in models of cognitive deficiency in animals. This review discusses evidence of the effects of (endo)cannabinoids and activation of the EC system on cognitive functions in the normal brain and in neurodegenerative diseases, Alzheimer's disease and temporal lobe epilepsy. Possible causes of inconsistencies in available data are also discussed.
引用
收藏
页码:3 / 38
页数:36
相关论文
共 50 条
  • [41] Phytocannabinoids, the Endocannabinoid System and Male Reproduction
    Lim, Jinhwan
    Squire, Erica
    Jung, Kwang-Mook
    WORLD JOURNAL OF MENS HEALTH, 2023, 41 (01) : 1 - 13
  • [42] Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies
    Kamaruzzaman, Mohd Amir
    Romli, Muhammad Hibatullah
    Abas, Razif
    Vidyadaran, Sharmili
    Baharuldin, Mohamad Taufik Hidayat
    Nasaruddin, Muhammad Luqman
    Thirupathirao, Vishnumukkala
    Sura, Sreenivasulu
    Warsito, Kabul
    Nor, Nurul Huda Mohd
    Azwaruddin, Muhammad Amsyar
    Alshawsh, Mohammed Abdullah
    Moklas, Mohamad Aris Mohd
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [43] The Endocannabinoid System in Alzheimer's Disease: A Network Meta-Analysis
    Liu, Yu
    Xing, Hang
    Zhang, Yan
    Song, Yi
    JOURNAL OF NEUROSCIENCE RESEARCH, 2024, 102 (09)
  • [44] Interplay Between Astroglial Endocannabinoid System and the Cognitive Dysfunction in Alzheimer's Disease
    Rapaka, Deepthi
    Adiukwu, Paul C.
    Challa, Siva Reddy
    Bitra, Veera Raghavulu
    PHYSIOLOGICAL RESEARCH, 2023, 72 (05) : 575 - 586
  • [45] Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review
    Camargo, Rick Wilhiam de
    de Novais Jr, Linerio Ribeiro
    da Silva, Larissa Mendes
    Meneguzzo, Vicente
    Daros, Guilherme Cabreira
    da Silva, Marina Goulart
    de Bitencourt, Rafael Mariano
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2022, 221
  • [46] Amyotrophic Lateral Sclerosis, the Endocannabinoid System, and Exogenous Cannabinoids: Current State and Clinical Implications
    Denton, Travis T.
    Carter, Gregory T.
    Goddard, Megan
    Weiss, Jeremy
    Weeks, Douglas L.
    Weydt, Patrick
    Russo, Ethan B.
    Weiss, Michael D.
    MUSCLE & NERVE, 2025,
  • [47] Conference on 'PUFA mediators: implications for human health' Symposium 3: Cannabinoids in human health Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications
    Pertwee, Roger G.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2014, 73 (01) : 96 - 105
  • [48] Allergic rhinitis and COVID-19: friends or foes?
    Gani, F.
    Cottini, M.
    Landi, M.
    Berti, A.
    Comberiati, P.
    Peroni, D.
    Senna, G.
    Lombardi, C.
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 54 (02) : 53 - 59
  • [49] The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes
    Nhan, Hoang S.
    Chiang, Karen
    Koo, Edward H.
    ACTA NEUROPATHOLOGICA, 2015, 129 (01) : 1 - 19
  • [50] The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases
    Kicman, Aleksandra
    Pedzinska-Betiuk, Anna
    Kozlowska, Hanna
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 911